![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Supertex, Inc. (MM) | NASDAQ:SUPX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 32.98 | 0 | 01:00:00 |
For the first six months ended October 2, 2010, net sales were $45,514,000 compared to $29,430,000 for the same period of the prior fiscal year, and on a GAAP basis, net income was $7,930,000, or $0.61 per diluted share, as compared with $1,988,000, or $0.15 per diluted share, in the same period of the prior fiscal year.
Non-GAAP earnings per diluted share for the second quarter of fiscal 2011 were $0.35, excluding pre-tax employee stock-based compensation of $818,000, compared with $0.37 in the prior quarter, excluding pre-tax employee stock based-compensation of $759,000, and $0.15 in the same quarter of the prior fiscal year, excluding pretax employee stock-based compensation of $835,000. For the six months ended October 2, 2010, non-GAAP net income per diluted share was $0.72, excluding pre-tax employee stock-based compensation of $1,577,000, as compared to $0.28 for the same period of the prior fiscal year, excluding pre-tax employee stock-based compensation of $1,655,000.
"The general market softness for LCD TVs with LED backlighting was the major cause of our overall sequential sales decline of 3%. This softness caused excess channel inventory of our LED drivers used in these TVs, which resulted in some of our customers requesting that we halt scheduled shipments of our drivers during the last two weeks of our second fiscal quarter," stated Dr. Henry C. Pao, President and CEO. "Fortunately, the global demand for our products for medical ultrasound systems was high, especially our new high voltage pulsers and T/R switches, which are being designed into many new models and are starting production ramp. The sequential growth of our medical electronics was 7%. Telecom and imaging product sales were down sequentially at 6% and 4%, respectively. Coming out of the recession, through the first half of fiscal 2011, our total sales have increased 55%, with all of our target markets having grown at double-digit rates. For our third fiscal quarter, although orders for our telecom products have increased significantly, we project our overall sales to be flat to 5% lower sequentially due to the normal seasonality decline in medical ultrasound products and continued softness in the demand for LCD TVs with LED backlighting. We believe the decline in LED driver sales for LCD TV backlighting is temporary and will recover once the inventory in the channel is reduced to normal levels."
"Gross margin for the second fiscal quarter was 56%, compared to 57% last quarter. Our fab capacity utilization remained high, at 71% vs. 76% last quarter," added Dr. Pao. "We have a large number of new products under development with many about to be introduced. At the same time, we have streamlined our R&D operations to control costs. Selling, general and administrative expenses were 17% higher sequentially due primarily to an increase in asset value of our non-qualified deferred compensation plan. This expense is offset in other income. Our tax rate was 34%, about the same as in the prior quarter. Inventories increased $2.9 million in the quarter, primarily due to reduced shipments at our customers' request, resulting from excess channel inventory of our LED drivers for backlighting LCD TVs, as described earlier. We generated approximately $4.2 million in operating cash flow in the quarter, extending our trend of consecutive positive cash flow quarters to 74. For the third fiscal quarter we forecast gross margin to be 55%-57% and our tax rate to be approximately 33%."
Forward-Looking Statements:
The industry in which we compete is characterized by extreme rapid changes in technology and frequent new product introductions. We believe that our long-term growth will depend largely on our ability to continue to enhance existing products and to introduce new products and features that meet the continually changing requirements of our customers. All statements contained in this press release that are not historical facts are forward-looking statements. They are not guarantees of future performance or events. They are based upon current expectations, estimates, beliefs, and assumptions about the future, which may prove incorrect, and upon our goals and objectives, which may change. Often such statements can be identified by the use of the words such as "will," "intends," "expects," "plans," "believes," "anticipates" and "estimates." Examples of forward-looking statements include our expectations that third fiscal quarter sales will be flat to 5% lower sequentially; gross margin will be 55% to 57%; and our tax rate will be 33% together with our beliefs that during the third fiscal quarter we will experience the normal seasonality decline in sales of our medical ultrasound products and continued softness in the demand for LCD TVs with LED backlighting and that the decline in LED driver sales for LCD TV backlighting is temporary and will recover once the inventory in the channel is reduced to normal levels.
These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. They are not guarantees of future performance or events but rather involve a number of risks and uncertainties including, but not limited to, whether our customers experience the demand we anticipate for their products based in part upon their input and our order backlog, whether the designed performance of our devices satisfies our customers' requirements so that they continue to design our devices into their products, whether our devices perform to their design specification, whether competitors introduce devices at lower prices than our devices causing price erosion, whether we encounter production issues in device manufacturing or moving new products from engineering into production, and whether our fab equipment continues to operate at expected capacities without need of replacement, as well as other risk factors detailed in our Form 8-K, 10-K, and 10-Q filings with the Securities and Exchange Commission. Due to these and other risks, our future actual results could differ materially from those discussed above. We undertake no obligation to publicly release updates or revisions to these statements that speak only as of this date.
Conference Call Details
The Company will host a conference call at 2:30 p.m. PDT (5:30 p.m. EDT) on October 26, 2010, following the earnings release. President and CEO, Dr. Henry C. Pao, VP, Marketing, Hernan DeGuzman and VP, Finance & CFO, Phil Kagel, will present an overview of the second fiscal quarter financial results, discuss current business conditions, and then respond to questions.
The call is available live for any interested party by dialing 800-862-9098 (domestic) or 785-424-1051 (toll, international) before the scheduled start time and using "Supertex" as conference ID. A recorded replay will be available for 30 days immediately following the conference call until 11:59 p.m. EDT, November 26, 2010 at 800-283-4783 (domestic) and 402-220-0859 (toll, international).
About Supertex
Supertex, Inc. is a publicly held mixed signal semiconductor manufacturer, focused in high voltage products for use in the medical ultrasound imaging, LCD TV backlighting, LED general lighting, telecommunications, printer, flat panel display, industrial and consumer product industries. Supertex product, corporate and financial information is readily available at our website: http://www.supertex.com.
For further information, contact Investor Relations at Supertex, Inc., 1235 Bordeaux Drive, Sunnyvale, California 94089, 408-222-8888 or visit our website at http://www.supertex.com.
Use of Non-GAAP Financial Information
To supplement our financial results presented in accordance with GAAP, we use the following non-GAAP financial measures: non-GAAP net income and diluted non-GAAP net income per share. We present such non-GAAP financial measures in reporting our financial results to provide investors with an additional tool to evaluate our operating results. Because these non-GAAP measures are not calculated in accordance with GAAP, they may not necessarily be comparable to similarly titled measures employed by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP measures, and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
Our management uses each of the above non-GAAP financial measures internally to understand, manage and evaluate our business. Our management believes it is useful for us and for investors to review, as applicable, both GAAP information, which includes employee stock-based compensation expense, and the non-GAAP measures, which exclude this information, in order to assess the performance of our core continuing businesses and for planning and forecasting in future periods. Each of these non-GAAP measures is intended to provide investors with an understanding of our operational results and trends that more readily enables them to analyze our base financial and operating performance and facilitate period-to-period comparisons and analysis of operation trends. Our management believes each of these non-GAAP financial measures is useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision-making.
Our GAAP cost of sales and operating expenses include employee stock-based compensation. Our non-GAAP financial measures reflect adjustments to exclude this employee stock-based compensation. We believe cost of sales excluding share-based compensation, R&D expense excluding share-based compensation, and SG&A expense excluding share-based compensation are useful information for investors because comparative differences in the corresponding GAAP measures for different periods may reflect factors such as a different stock price when equity awards were made and different equity award practices rather than changes in the operation of the business. Stock options are the form of equity compensation we presently utilize and they are a key incentive we offer our employees. We believe they have contributed to the sales earned during the period and will contribute to our future sales generation. Employee stock-based compensation expenses will recur in future periods.
SUPERTEX, INC. CONSOLIDATED BALANCE SHEET INFORMATION (unaudited) October 2, 2010 April 3, 2010 ---------------- ---------------- (in thousands) ASSETS Cash and cash equivalents $ 16,851 $ 10,153 Short term investments 101,623 76,860 Trade accounts receivable, net 12,037 10,786 Inventories 19,397 15,450 Deferred income taxes 7,819 8,162 Prepaid income taxes 2,268 2,456 Prepaid expenses and other current assets 2,851 3,726 ---------------- ---------------- Total current assets 162,846 127,593 Long term investments 47,300 65,000 Property, plant and equipment, net 6,397 6,791 Other assets 665 580 Deferred income taxes 4,329 5,254 ---------------- ---------------- TOTAL ASSETS $ 221,537 $ 205,218 ================ ================ LIABILITIES Trade accounts payable $ 5,407 $ 3,748 Accrued salaries and employee benefits 12,559 11,430 Other accrued liabilities 1,440 1,167 Deferred revenue 4,467 3,962 Income taxes payable 241 15 ---------------- ---------------- Total current liabilities 24,114 20,322 Income taxes payable, noncurrent 5,219 4,520 ---------------- ---------------- Total liabilities 29,333 24,842 SHAREHOLDERS' EQUITY Common stock 66,941 64,296 Accumulated other comprehensive loss (1,313) (2,566) Retained earnings 126,576 118,646 ---------------- ---------------- Total shareholders' equity 192,204 180,376 ---------------- ---------------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 221,537 $ 205,218 ================ ================ SUPERTEX, INC. CONSOLIDATED INCOME STATEMENT INFORMATION (unaudited) Three Months Ended Six Months Ended --------------------- --------------------- (in thousands, except per share amounts) October 2, September October 2, September 2010 26, 2009 2010 26, 2009 ---------- ---------- ---------- ---------- Net sales $ 22,359 $ 15,875 $ 45,514 $ 29,430 Cost of sales(1) 9,819 8,474 19,780 14,899 ---------- ---------- ---------- ---------- Gross profit 12,540 7,401 25,734 14,531 Research and development(1) 3,620 3,604 7,131 7,609 Selling, general and administrative(1) 3,861 3,158 7,172 5,948 ---------- ---------- ---------- ---------- Income from operations 5,059 639 11,431 974 Interest and other income, net 723 853 634 1,639 ---------- ---------- ---------- ---------- Income before income taxes 5,782 1,492 12,065 2,613 Provision for income taxes 1,960 409 4,135 625 ---------- ---------- ---------- ---------- Net income $ 3,822 $ 1,083 $ 7,930 $ 1,988 ========== ========== ========== ========== Net income per share: Basic $ 0.29 $ 0.08 $ 0.61 $ 0.15 ========== ========== ========== ========== Diluted $ 0.29 $ 0.08 $ 0.61 $ 0.15 ========== ========== ========== ========== Shares used in per share computation: Basic 12,991 12,902 12,974 12,893 ========== ========== ========== ========== Diluted 13,048 12,987 13,044 12,977 ========== ========== ========== ========== (1) Includes amortization of employee stock-based compensation as follows: Cost of sales $ 179 $ 196 $ 329 $ 344 Research and development $ 323 $ 342 $ 676 $ 731 Selling, general and administrative $ 316 $ 297 $ 572 $ 580 SUPERTEX, INC. SUPPLEMENTAL RECONCILIATIONS OF GAAP TO NON-GAAP RESULTS (unaudited) Three Months Ended Six Months Ended ---------------------- ---------------------- (in thousands, except per share amounts) October 2, September October 2, September 2010 26, 2009 2010 26, 2009 ---------- ---------- ---------- ---------- GAAP net income $ 3,822 $ 1,083 $ 7,930 $ 1,988 Adjustment for stock-based compensation included in: Cost of sales 179 196 329 344 Research and development 323 342 676 731 Selling, general and administrative 316 297 572 580 ---------- ---------- ---------- ---------- Subtotal 818 835 1,577 1,655 Tax effect of stock-based compensation (36) (26) (59) (51) ---------- ---------- ---------- ---------- Non-GAAP net income excluding employee stock-based compensation $ 4,604 $ 1,892 $ 9,448 $ 3,592 ========== ========== ========== ========== Non-GAAP net income per share: Basic $ 0.35 $ 0.15 $ 0.73 $ 0.28 ========== ========== ========== ========== Diluted $ 0.35 $ 0.15 $ 0.72 $ 0.28 ========== ========== ========== ========== Shares used in per share computation: Basic 12,991 12,902 12,974 12,893 ========== ========== ========== ========== Diluted 13,048 12,987 13,044 12,977 ========== ========== ========== ========== SUPERTEX, INC. SUPPLEMENTAL RECONCILIATIONS OF GAAP TO NON-GAAP INCOME PER SHARE (unaudited) Three Months Ended Six Months Ended ---------------------- ---------------------- (in thousands, except per share amounts) October 2, September October 2, September 2010 26, 2009 2010 26, 2009 ---------- ---------- ---------- ---------- Shares used in per share computation: Diluted 13,048 12,987 13,044 12,977 ========== ========== ========== ========== DILUTED: GAAP net income per share $ 0.29 $ 0.08 $ 0.61 $ 0.15 Adjustments to reconcile net income to non-GAAP net income per share: Employee stock-based compensation effects included in: Cost of sales 0.01 0.02 0.02 0.03 Research and development 0.03 0.03 0.05 0.06 Selling, general and administrative 0.02 0.02 0.04 0.04 Provision for income taxes (0.00) (0.00) (0.00) (0.00) ---------- ---------- ---------- ---------- Non-GAAP net income per share excluding employee stock-based compensation $ 0.35 $ 0.15 $ 0.72 $ 0.28 ========== ========== ========== ==========
Corporate Headquarters: Dr. Henry C. Pao President & CEO 408/222-8888
1 Year Supertex Chart |
1 Month Supertex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions